Cargando…
Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19
With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527889/ https://www.ncbi.nlm.nih.gov/pubmed/34710657 http://dx.doi.org/10.1016/j.intimp.2021.108254 |
_version_ | 1784586158456438784 |
---|---|
author | Zhou, Bangyi Li, Siying Ye, Jujian Liu, Yi Hu, Longtai Tang, Yan Wu, Zhijian Zhang, Peidong |
author_facet | Zhou, Bangyi Li, Siying Ye, Jujian Liu, Yi Hu, Longtai Tang, Yan Wu, Zhijian Zhang, Peidong |
author_sort | Zhou, Bangyi |
collection | PubMed |
description | With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of both COVID-19 and SLE. In the early stages of COVID-19 and SLE pathogenesis, IFN-α expression is frequently increased, which aggravates the virus infection and promotes SLE development. In addition, increased IL-6 levels, caused by different mechanisms, are observed in the peripheral blood of patients with severe COVID-19 and SLE, stimulating a series of immune cascades that lead to a cytokine storm, as well as causing B cell hyperfunction and production of numerous of antibodies, aggravating both COVID-19 and SLE. In this review, we explore the background immunopathological mechanisms in COVID-19 and SLE and analyze the advantages and disadvantages of commonly used SLE drugs for patients with COVID-19, to optimize treatment plans for patients with SLE who develop COVID-19. |
format | Online Article Text |
id | pubmed-8527889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85278892021-10-21 Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 Zhou, Bangyi Li, Siying Ye, Jujian Liu, Yi Hu, Longtai Tang, Yan Wu, Zhijian Zhang, Peidong Int Immunopharmacol Article With the outbreak and rapid spread of COVID-19, the world health situation is unprecedentedly severe. Systemic lupus erythematosus (SLE) is a common autoimmune disease, which can cause multiple organ damage. Numerous studies have shown that immune factors have important roles in the pathogenesis of both COVID-19 and SLE. In the early stages of COVID-19 and SLE pathogenesis, IFN-α expression is frequently increased, which aggravates the virus infection and promotes SLE development. In addition, increased IL-6 levels, caused by different mechanisms, are observed in the peripheral blood of patients with severe COVID-19 and SLE, stimulating a series of immune cascades that lead to a cytokine storm, as well as causing B cell hyperfunction and production of numerous of antibodies, aggravating both COVID-19 and SLE. In this review, we explore the background immunopathological mechanisms in COVID-19 and SLE and analyze the advantages and disadvantages of commonly used SLE drugs for patients with COVID-19, to optimize treatment plans for patients with SLE who develop COVID-19. Published by Elsevier B.V. 2021-12 2021-10-14 /pmc/articles/PMC8527889/ /pubmed/34710657 http://dx.doi.org/10.1016/j.intimp.2021.108254 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zhou, Bangyi Li, Siying Ye, Jujian Liu, Yi Hu, Longtai Tang, Yan Wu, Zhijian Zhang, Peidong Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title | Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title_full | Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title_fullStr | Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title_full_unstemmed | Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title_short | Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19 |
title_sort | immunopathological events surrounding il-6 and ifn-α: a bridge for anti-lupus erythematosus drugs used to treat covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527889/ https://www.ncbi.nlm.nih.gov/pubmed/34710657 http://dx.doi.org/10.1016/j.intimp.2021.108254 |
work_keys_str_mv | AT zhoubangyi immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT lisiying immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT yejujian immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT liuyi immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT hulongtai immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT tangyan immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT wuzhijian immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 AT zhangpeidong immunopathologicaleventssurroundingil6andifnaabridgeforantilupuserythematosusdrugsusedtotreatcovid19 |